Screening & TReatment fOr Perinatal WomeN With PTSD in Substance Use Care SettinGs in Arkansas (STRONG Moms) (STRONG Moms)
研究概览
详细说明
The primary objective is to evaluate the feasibility and acceptability of implementing a brief, telehealth-delivered behavioral intervention for PTSD among pregnant and postpartum individuals with a history of substance misuse. Secondary objectives include estimating the prevalence of probable PTSD in perinatal substance use treatment settings, assessing participant interest in receiving PTSD treatment while engaged in substance use care, and examining preliminary changes in PTSD and depressive symptoms following treatment.
The study consists of two sequential components. First, pregnant and postpartum individuals receiving services for problematic substance misuse in Arkansas will be screened for PTSD symptoms using the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5). Screening will be conducted across multiple treatment and care settings, including inpatient and outpatient programs, to estimate the prevalence of probable PTSD and characterize willingness to participate in trauma-focused treatment during the perinatal period.
Second, individuals who meet eligibility criteria for PTSD treatment will participate in a mixed-methods, single-arm pre-post pilot evaluation of Written Exposure Therapy (WET), a brief evidence-based behavioral intervention for PTSD delivered via telehealth. Approximately 20 pregnant and postpartum participants with PTSD will receive the intervention. Feasibility will be assessed through measures such as recruitment, enrollment, retention, intervention completion, and assessment completion. Acceptability will be evaluated using participant-reported satisfaction and qualitative interviews exploring experiences with treatment delivery, barriers and facilitators to participation, and recommendations for implementation. Clinical assessments conducted before and after treatment will provide preliminary estimates of changes in PTSD symptoms and depressive symptoms.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Mollee K. Steely Smith K Assistant Professor, PhD
- 电话号码:501-526-8174
- 邮箱:mksteelysmith@uams.edu
研究联系人备份
- 姓名:Chelsey E Bull, PhD
- 邮箱:cebull@uams.edu
学习地点
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- University of Arkansas for Medical Sciences
-
接触:
- Mollee K Steely Smith, PhD
- 电话号码:501-526-8174
- 邮箱:mksteelysmith@uams.edu
-
接触:
- Chelsey E Bull, PhD
- 邮箱:cebull@uams.edu
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Able to write, understand, and speak English
- Able to give informed consent
- Currently pregnant or postpartum (≤ 6 months after childbirth)
- History of substance misuse
- Receiving services for substance-use related problems
- Have a history of traumatic event exposure
- Endorse clinically significant PTSD symptoms (score ≥ 3 on the Primary Care PTSD Screen for DSM-5; PC-PTSD-5)
Exclusion Criteria:
- Unwilling to provide consent
- No history of Criterion A trauma exposure or clinically significant PTSD symptoms
- No history of substance misuse or currently receiving services for a substance-use related problem
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single Arm Intervention
All participants will receive Written Exposure Therapy (WET)
|
Written Exposure Therapy (WET) is a brief, evidence-based therapy for PTSD.
Clients receive 5 weekly sessions where they write about a traumatic experience in a safe, structured way for approximately 50 minutes followed by a brief check-in with their therapist.
This process helps individuals make sense of the event, reduce emotional distress, and decrease PTSD symptoms over time.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Acceptability
大体时间:From baseline to end of treatment at 5 weeks
|
Acceptability will be evaluated using the Client Satisfaction Questionnaire (CSQ-8), an 8-item participant-reported satisfaction measure rated on a 4-point Likert scale.
Total scores ranging from 8-32, with higher scores indicating greater satisfaction with the therapy.
|
From baseline to end of treatment at 5 weeks
|
|
Acceptability
大体时间:From baseline to end of treatment at 5 weeks
|
Acceptability will also be evaluated using the Acceptability of Intervention (AIM), which is a 4-item self-reported questionnaire on a 5-point Likert scale assessing acceptability of the intervention.
Scores are summed and higher scores indicate greater acceptability.
|
From baseline to end of treatment at 5 weeks
|
|
Feasibility of Recruitment
大体时间:From enrollment to end of treatment at 5 weeks
|
Feasibility of recruitment will be assessed by the number of individuals who initiated WET versus the total number of individuals enrolled in the study.
|
From enrollment to end of treatment at 5 weeks
|
|
Therapy Adherence
大体时间:From enrollment to end of treatment at 5 weeks
|
Therapy adherence will be assessed by WET session attendance and completion.
We will measure therapy adherence by the number of individuals who complete ≥ 4 sessions versus the total number of individuals who received ≤ 3 sessions.
|
From enrollment to end of treatment at 5 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PTSD Symptoms
大体时间:From enrollment to the end of treatment at 5 weeks
|
Changes in PTSD symptoms will be assessed using the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report questionnaire on symptoms of PTSD.
Scores range from 0-80, with higher scores indicating a greater PTSD symptom severity.
|
From enrollment to the end of treatment at 5 weeks
|
|
Depression Symptoms
大体时间:From enrollment to end of treatment at 5 weeks
|
Depression symptoms will be assessed using the Personal History Questionnaire (PHQ-9), a 9-item questionnaire used to assess depression symptoms over the past 2 weeks.
Total scores range from 0-27, with higher scores indicating greater severity of depression symptoms
|
From enrollment to end of treatment at 5 weeks
|
|
Substance Use Severity
大体时间:From enrollment to end of treatment at 5 weeks
|
The DSM-5 Drug Use Disorder (DUD) and Alcohol Use Disorder (AUD) Symptom Checklist is a self-report measure to assess the presence of diagnostic criteria for drug use disorders.
This measure evaluates the 11 DSM-5 criteria for drug use disorders, including impaired control, social impairment, risky use, and pharmacologic indicators (tolerance/withdrawal).
Endorsement of a greater number of criteria indicates greater severity and can be categorized as mild, moderate, or severe.
|
From enrollment to end of treatment at 5 weeks
|
|
Pre/Postnatal Depression Symptoms
大体时间:From enrollment to the end of treatment at 5 weeks
|
The Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-report questionnaire to assess depressive symptoms experiences during the previous 7 days in pregnant and postpartum individuals, will also be used to assess perinatal postpartum depression.
Total scores range from 0-30, with higher scores indicating greater severity of depressive symptoms.
|
From enrollment to the end of treatment at 5 weeks
|
合作者和调查者
调查人员
- 首席研究员:Mollee K Steely Smith, PhD、University of Arkansas
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.